Study identifier:NIS-NIT-DUM-2010/1
ClinicalTrials.gov identifier:N/A
EudraCT identifier:N/A
CTIS identifier:N/A
A non - interventional study to Investigating the ratio of Mis-diagnosed bipolar symptoms in Patient diagnosed as with treatment Resistant major depressive disorder (MDD)
Major depressive disorder
-
No
-
All
660
Observational
18 Years - 65 Years
Allocation: -
Endpoint Classification: -
Intervention Model: -
Masking: -
Primary Purpose: -
Verified 01 Nov 2013 by AstraZeneca
AstraZeneca
-
The study will only detect hypomanic symptoms in treatment resistant MDD patients by mean of HCL-32 administration. Further re-evaluation of MDD diagnosis is not a direct aim of the study. No efficacy and tolerability of pharmacological treatments will be assessed. Patients matching inclusion and exclusion criteria will be enrolled consecutively; each investigator will include the first 10 to 40 patients that will be visited as treatment resistant MDD.
Location
Location
Capaccio, SA, Italy
Location
Ortona, CH, Italy
Location
Adrano-Bronte, CT, Italy
Location
Agrigento, AG, Italy
Location
Ancona, AN, Italy
Location
Bolzano, BZ, Italy
Location
Cagliari, CA, Italy
Location
Cantu, CO, Italy
Arms | Assigned Interventions |
---|---|
MDD Patients with treatment resistant major depressive disorder will be evaluated in order to assess the presence of hypomanic symptoms as cause of resistance. | - |
This information is not intended to replace the informed medical advice or medical treatments of a healthcare professional. Only a physician can determine if a specific medicine is the correct treatment for a particular patient. If you have questions regarding any information contained in this site, you must consult a suitably qualified healthcare professional. Before prescribing any AstraZeneca products, Healthcare Professionals should view their country specific information.